Loxoprofen-d3
Loxoprofen-d3 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity.
For research use only. We do not sell to patients.
- Formula: C15H15D3O3
- Molecular Weight:249.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 68767-14-6
-
Molecular Weight 249.32
-
Formula C15H15D3O3
-
SMILES
O=C1CCCC1CC2=CC=C(C=C2)C(C(O)=O)C([2H])([2H])[2H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : ≥ 100 mg/mL (401.09 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Hamaguchi M, et al. Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation. J Clin Biochem Nutr. 2010 Sep;47(2):138-47. [Content Brief]
[3]. Riendeau D, et al. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004;14(5):1201-1203. [Content Brief]
[4]. Kanda A, et al. Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. Acta Oncol. 2003;42(1):62-70. [Content Brief]
[5]. Paudel S, et al. Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators. Pharmaceutics. 2019;11(9):479. Published 2019 Sep 16. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0109 mL | 20.0545 mL | 40.1091 mL | 100.2727 mL |
| 5 mM | 0.8022 mL | 4.0109 mL | 8.0218 mL | 20.0545 mL | |
| 10 mM | 0.4011 mL | 2.0055 mL | 4.0109 mL | 10.0273 mL | |
| 15 mM | 0.2674 mL | 1.3370 mL | 2.6739 mL | 6.6848 mL | |
| 20 mM | 0.2005 mL | 1.0027 mL | 2.0055 mL | 5.0136 mL | |
| 25 mM | 0.1604 mL | 0.8022 mL | 1.6044 mL | 4.0109 mL | |
| 30 mM | 0.1337 mL | 0.6685 mL | 1.3370 mL | 3.3424 mL | |
| 40 mM | 0.1003 mL | 0.5014 mL | 1.0027 mL | 2.5068 mL | |
| 50 mM | 0.0802 mL | 0.4011 mL | 0.8022 mL | 2.0055 mL | |
| 60 mM | 0.0668 mL | 0.3342 mL | 0.6685 mL | 1.6712 mL | |
| 80 mM | 0.0501 mL | 0.2507 mL | 0.5014 mL | 1.2534 mL | |
| 100 mM | 0.0401 mL | 0.2005 mL | 0.4011 mL | 1.0027 mL |